A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes

被引:150
作者
Ando, Hiroyuki [1 ,2 ,3 ]
Yoshinaga, Takashi [1 ,2 ,4 ]
Yamamotoa, Wataru [1 ,5 ]
Asakura, Keiichi [1 ,2 ,6 ]
Uda, Takaaki [1 ,3 ]
Taniguchi, Tomohiko [1 ,4 ]
Ojima, Atsuko [1 ,4 ]
Shinkyo, Raku [4 ]
Kikuchi, Kiyomi [4 ]
Osada, Tomoharu [1 ,2 ,7 ]
Hayashi, Seiji [1 ,2 ,6 ]
Kasai, Chieko [1 ,2 ,8 ]
Miyamotoa, Norimasa [1 ,4 ]
Tashibu, Hiroyuki [1 ,2 ,9 ]
Yamazaki, Daiju [1 ,10 ]
Sugiyama, Atsushi [1 ,2 ,11 ]
Kanda, Yasunari [1 ,10 ]
Sawada, Kohei [1 ,2 ,4 ]
Sekino, Yuko [1 ,2 ,10 ]
机构
[1] Japan IPS Cardiac Safety Assessment JiCSA, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan
[2] JSPS, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan
[3] Ono Pharmaceut Co Ltd, Safety Res Labs, 50-10 Yamagishi,Mikuni Cho, Sakai, Fukui 9138538, Japan
[4] Eisai & Co Ltd, Med Dev Ctr, Biopharmaceut Assessments Core Funct Unit, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan
[5] Teijin Pharma Ltd, Toxicol Res Dept, Pharmaceut Dev Res Labs, 4-3-2 Asahigaoka, Hino, Tokyo 1918512, Japan
[6] Nippon Shinyaku Co Ltd, Discovery Res Labs, Minami Ku, 14 Nishinosho Monguchi Cho, Kyoto 6018550, Japan
[7] LSI Med Corp, Drug Dev Serv Segment, Chiyoda Ku, 13-4 Uchikando 1 Chome, Tokyo 1018517, Japan
[8] Astellas Pharma Inc, Drug Safety Res Labs, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan
[9] Ina Res Inc, Res Adm Dept, 2148-188 Nishiminowa, Ina, Nagano 3994501, Japan
[10] NIHS, Div Pharmacol, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan
[11] Toho Univ, Fac Med, Dept Pharmacol, Ota Ku, 5-21-16 Omori Nishi, Tokyo 1438540, Japan
关键词
Concordance; Early afterdepolarization; Field potential duration; Free concentration; Human induced plunpotent stein cell-derived cardiomyocytes Miati-electrode array; Proarrhythmia; Risk categorisation; Torsadc de pointes; Torsadogenic risk; ACTIVATING DELAYED RECTIFIER; MULTIELECTRODE ARRAY; TRANSIENT OUTWARD; ACTION-POTENTIALS; QT PROLONGATION; K+ CHANNEL; DE-POINTES; HERG; VALIDATION; ARRHYTHMIA;
D O I
10.1016/j.vascn.2016.12.003
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Introduction: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) arc anticipated to be a useful tool for conducting proarrhythmia risk assessments of drug candidates. However, a torsadogenic risk prediction paradigm using hiPSC-CMs has not yet been fully established. Methods: Extracellular field potentials (Hs) were recorded from hiPSC-CMs using the multi-electrode array (MEA) system. The effects on FPs were evaluated with 60 drugs, including 57 with various clinical torsadogenic risks. Actual drug concentrations in medium were measured using the equilibrium dialysis method with a Rapid Equilibrium Dialysis device. Relative torsade de pointes (TdP) scores were determined for each drug according to the degree of FP duration prolongation and early afterdepolarization occurrence. The margins were calculated from the free concentration in medium and free effective therapeutic plasma concentration. Each drug's results were plotted on a two-dimensional map of relative TdP risk scores versus margins. Results: Each drug was categorised as high, intermediate, or low risk based on its location within predefined areas of the two-dimensional map. We categorised 19 drugs as high risk; 18 as intermediate risk; and 17 as low risk. We examined the concordance between our categorisation of high and low risk drugs against the lorsadogenic risk categorisation in CreclibleMeds. Our system demonstrated high concordance, as reflected in a sensitivity of 81%, specificity of 87%, and accuracy of 83%. Discussion: These results indicate that our lorsadogenic risk assessment is reliable and has a potential lo replace the hERG assay for torsaclogenic risk prediction, however, this system needs to be improved for the accurate of prediction of clinical TdP risk. Here, we propose a novel drug induced torsadogenic risk categorising system using hiPSC-CMs and the MEA system. (C) 2016 The Authors. Published by Elsevier Inc This is an open access article under the CC BY-NC-ND license
引用
收藏
页码:111 / 127
页数:17
相关论文
共 85 条
[1]
[Anonymous], 1991, Circulation, V84, P1831
[2]
[Anonymous], 2014, ANZEMET TABLETS DOLA
[3]
[Anonymous], 2000, Clinical Pharmacology and Biopharmaceutics Review
[4]
[Anonymous], 2016, DETRUSITOL CAPSULES
[5]
[Anonymous], 2011, CLIN PHARM BIOPH REV
[6]
[Anonymous], 2008, VENA TABLETS INTERVI
[7]
[Anonymous], 2015, CLOZARIL TABLETS CLO
[8]
[Anonymous], 2014, BAYASPIRINL 100 MG A
[9]
Electrophysiologic basis for the antiarrhythmic actions of ranolazine [J].
Antzelevitch, Charles ;
Burashnikov, Alexander ;
Sicouri, Serge ;
Belardinelli, Luiz .
HEART RHYTHM, 2011, 8 (08) :1281-1290
[10]
Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes [J].
Asakura, Keiichi ;
Hayashi, Seiji ;
Ojima, Atsuko ;
Taniguchi, Tomohiko ;
Miyamoto, Norimasa ;
Nakamori, Chiaki ;
Nagasawa, Chiho ;
Kitamura, Tetsuo ;
Osada, Tomoharu ;
Honda, Yayoi ;
Kasai, Chieko ;
Ando, Hiroyuki ;
Kanda, Yasunari ;
Sekino, Yuko ;
Sawada, Kohei .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2015, 75 :17-26